191 related articles for article (PubMed ID: 32030538)
1. Quantification of T Cell Binding Polyclonal Rabbit Anti-thymocyte Globulin in Human Plasma with Liquid Chromatography Tandem-Mass Spectrometry.
Amrani ME; Admiraal R; Willaert L; Ebskamp-van Raaij LJC; Lacna AM; Hack CE; Huitema ADR; Nierkens S; van Maarseveen EM
AAPS J; 2020 Feb; 22(2):43. PubMed ID: 32030538
[TBL] [Abstract][Full Text] [Related]
2. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis.
Admiraal R; van Kesteren C; Jol-van der Zijde CM; Lankester AC; Bierings MB; Egberts TC; van Tol MJ; Knibbe CA; Bredius RG; Boelens JJ
Lancet Haematol; 2015 May; 2(5):e194-203. PubMed ID: 26688094
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring of Anti-Thymocyte Globulin in Allogeneic Stem Cell Transplantation: Proof of Concept.
Meesters-Ensing JI; Admiraal R; Ebskamp L; Lacna A; Boelens JJ; Lindemans CA; Nierkens S
Front Pharmacol; 2022; 13():828094. PubMed ID: 35370695
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation.
Waller EK; Langston AA; Lonial S; Cherry J; Somani J; Allen AJ; Rosenthal H; Redei I
Biol Blood Marrow Transplant; 2003 Jul; 9(7):460-71. PubMed ID: 12869960
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous clearance of antithymocyte globulin after CD34+-selected allogeneic hematopoietic progenitor cell transplantation.
Kakhniashvili I; Filicko J; Kraft WK; Flomenberg N
Biol Blood Marrow Transplant; 2005 Aug; 11(8):609-18. PubMed ID: 16041311
[TBL] [Abstract][Full Text] [Related]
6. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
7. Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation.
Storek J; Mohty M; Boelens JJ
Biol Blood Marrow Transplant; 2015 Jun; 21(6):959-70. PubMed ID: 25482864
[TBL] [Abstract][Full Text] [Related]
8. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis.
Admiraal R; Nierkens S; de Witte MA; Petersen EJ; Fleurke GJ; Verrest L; Belitser SV; Bredius RGM; Raymakers RAP; Knibbe CAJ; Minnema MC; van Kesteren C; Kuball J; Boelens JJ
Lancet Haematol; 2017 Apr; 4(4):e183-e191. PubMed ID: 28330607
[TBL] [Abstract][Full Text] [Related]
9. Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse.
Hoegh-Petersen M; Amin MA; Liu Y; Ugarte-Torres A; Williamson TS; Podgorny PJ; Russell JA; Grigg A; Ritchie D; Storek J
Bone Marrow Transplant; 2013 Jan; 48(1):105-14. PubMed ID: 22659684
[TBL] [Abstract][Full Text] [Related]
10. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
[TBL] [Abstract][Full Text] [Related]
11. Jurkat cell-reactive anti-thymocyte globulin assessed ex vivo by flow cytometry persists three weeks in circulation.
Eiermann TH; Freitag S; Cortes-Dericks L; Sahm H; Zander AR
J Hematother Stem Cell Res; 2001 Jun; 10(3):385-90. PubMed ID: 11454313
[TBL] [Abstract][Full Text] [Related]
12. Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.
Ecsedi M; Schmohl J; Zeiser R; Drexler B; Halter J; Medinger M; Duyster J; Kanz L; Passweg J; Finke J; Bethge W; Lengerke C
Ann Hematol; 2016 Oct; 95(10):1627-36. PubMed ID: 27480090
[TBL] [Abstract][Full Text] [Related]
13. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
[TBL] [Abstract][Full Text] [Related]
14. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation.
Bosch M; Dhadda M; Hoegh-Petersen M; Liu Y; Hagel LM; Podgorny P; Ugarte-Torres A; Khan FM; Luider J; Auer-Grzesiak I; Mansoor A; Russell JA; Daly A; Stewart DA; Maloney D; Boeckh M; Storek J
Cytotherapy; 2012 Nov; 14(10):1258-75. PubMed ID: 22985195
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning.
Punt AM; Langenhorst JB; Egas AC; Boelens JJ; van Kesteren C; van Maarseveen EM
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jun; 1055-1056():81-85. PubMed ID: 28445850
[TBL] [Abstract][Full Text] [Related]
16. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder.
Podgorny PJ; Ugarte-Torres A; Liu Y; Williamson TS; Russell JA; Storek J
Biol Blood Marrow Transplant; 2010 Jul; 16(7):915-26. PubMed ID: 20226870
[TBL] [Abstract][Full Text] [Related]
17. Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
Butera S; Cerrano M; Brunello L; Dellacasa CM; Faraci DG; Vassallo S; Mordini N; Sorasio R; Zallio F; Busca A; Bruno B; Giaccone L
Ann Hematol; 2021 Jul; 100(7):1837-1847. PubMed ID: 33948721
[TBL] [Abstract][Full Text] [Related]
18. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D
Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377
[TBL] [Abstract][Full Text] [Related]
19. Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease.
Khanolkar RA; Tripathi G; Dharmani-Khan P; Dabas R; Kinzel M; Kalra A; Puckrin R; Jimenez-Zepeda V; Jamani K; Duggan PR; Chaudhry A; Bryant A; Stewart DA; Khan FM; Storek J
Cytotherapy; 2022 Dec; 24(12):1225-1231. PubMed ID: 36057497
[TBL] [Abstract][Full Text] [Related]
20. Impact of low-dose anti-thymocyte globulin on immune reconstitution after allogeneic hematopoietic cell transplantation.
Ito A; Kitano S; Tajima K; Kim Y; Tanaka T; Inamoto Y; Kim SW; Yamamoto N; Fukuda T; Okamoto S
Int J Hematol; 2020 Jan; 111(1):120-130. PubMed ID: 31641956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
